stockrow
Saturday 7 November 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024.
- Revenue
- +14,590.2%
- EPS
- −72.4%
- Free cash flow
- −56.7%
Quarter to June 2026, against a year earlier
2.95
0.19
+6.88%
Follow EVAX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 3 | 8 | 11 | +915.5% | — | 5 | 10 | +10.9% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | (6) | (12) | (17) | (25) | (24) | (23) | (11) | (9) | (8) | +4.7% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (31,390.41) | (339.56) | (114.44) | 0.00 | (114.4) pt | ||||||
| Net income | — | 0 | (6) | (11) | (15) | (25) | (23) | (22) | (11) | (8) | (7) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 3.12 | 1.17 | 0.00 | n/m | |||||
| Earnings | — | — | (21.43) | (40.29) | (48.50) | (63.00) | (49.00) | (40.47) | (9.85) | (1.20) | (0.97) | (33.7%) | ||||||
| Cash flow | — | — | (7.65) | (25.27) | (40.29) | (56.25) | (54.51) | (32.36) | (12.06) | (1.03) | (4.04) | (24.9%) | ||||||
| Capex | — | — | 0.00 | (0.22) | (0.60) | (3.49) | (0.62) | (0.16) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (7.65) | (25.49) | (40.89) | (59.74) | (55.13) | (32.52) | (12.06) | (1.04) | (4.04) | (24.8%) | ||||||
| Book value | — | — | (3.60) | 33.70 | 22.80 | 83.19 | 17.56 | (8.65) | (1.54) | 2.66 | 1.28 | n/m | ||||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 7 | +58.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 2.84 | 2.06 | 0.9 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.78 | 2.31 | 0.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.33 | 1.38 | 0.4 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (3.61) | (0.32) | (0.47) | (0.48) | (1.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (7) | (12) | (22) | (26) | (18) | (13) | (7) | (30) | +18.9% | |||||
| Capex | — | — | 0 | 0 | 0 | (1) | 0 | 0 | — | 0 | 0 | +6.7% | ||||||
| Free cash flow | — | — | (2) | (7) | (13) | (23) | (26) | (18) | (13) | (7) | (30) | +18.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (1) | 9 | 6 | 30 | 13 | 1 | 4 | 21 | 13 | n/m | |||||
| Net debt | — | — | 1 | (10) | (6) | (29) | (3) | 5 | 4 | (16) | (7) | n/m | ||||||
| Shareholders’ equity | — | — | (1) | 9 | 7 | 32 | 8 | (5) | (2) | 17 | 10 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (129.91) | (114.25) | (130.31) | (94.12) | (74.51) | (126.74) | (83.29) | (37.69) | (36.20) | +92.2 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (846.00) | (442.73) | (311.38) | (5,979.80) | (421.78) | (608.14) | (245.79) | (608.1) pt | ||||||
| ROE | — | — | (131.17) | (265.57) | (183.15) | (124.29) | (113.74) | (1,238.11) | 331.20 | (100.18) | (96.10) | +31.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 35 | 61 | 60 | 49 | 46 | 46 | — | +5.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.16 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2025 · fundamentals updated 26 Oct 2026
Evaxion A/S - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics, Inc. | $24.3M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | Compare |
| CVM Cel-Sci Corporation | $24.1M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $23.5M | — (loss-making) | — (loss-making) | −5.30% (below 0%: shrinking) | n/m | −10.91% (below 0%: shrinking) | 56.79% | (78.00%) | Compare |
| NXTC NextCure, Inc. | $23.4M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.0M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | |
| IGC IGC Pharma, Inc. | $22.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −45.33% (below 0%: shrinking) | 18.60% | (588.72%) | Compare |
| CRVO CervoMed Inc. | $21.9M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FLNA Cassava Sciences, Inc. | $21.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MCRB Seres Therapeutics, Inc. | $20.8M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −576.66% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| Median of peers | $22.7M | — | — | 0.00% | — | −8.55% | 18.60% | 0.00% |